EQL Pharma AB announced that its key product Mellozzan® has now gained marketing approval by the Health Authorities in Germany and Austria, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Pütter GmbH & Co. KG. Launch of Mellozzan in Germany and Austria are planned for 2024, subject to reimbursement approvals and manufacturing capabilities.

In addition to Germany and Austria the licensee also has ongoing work for registrations and subsequent launches in the UK, Finland and Switzerland. Earlier this year Medice launched Mellozzan in Denmark and Norway. In addition to the countries covered by Medice, other partners for Mellozzan® are in various stages of registration in France, Italy, Spain, the Netherlands, Turkey and Kazakhstan.

Furthermore, EQL has entered into a global license agreement covering 89 countries with Adalvo for Mellozzan®.